Asthika Goonewardene
Stock Analyst at Truist Financial
Total Price Targets
9
Stocks Covered
6
Sectors
Healthcare
Most Recent
Dec 17, 2025
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Asthika Goonewardene
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| ZYME | Zymeworks Inc. | $40.00 | $26.93 | +48.6% | 1 | Dec 17, 2025 |
| CRBU | Caribou Biosciences, Inc. | $7.00 | $1.89 | +271.4% | 1 | Nov 4, 2025 |
| RCUS | Arcus Biosciences, Inc. | $39.00 | $25.66 | +52.0% | 2 | Oct 7, 2025 |
| EXEL | Exelixis, Inc. | $56.00 | $43.81 | +27.8% | 3 | Jul 15, 2025 |
| GILD | Gilead Sciences, Inc. | $83.00 | $132.04 | -37.1% | 1 | Aug 14, 2024 |
| CELU | Celularity Inc. | $3.00 | $0.96 | +212.4% | 1 | Aug 23, 2022 |
Recent Activity
- Dec 17, 2025— Set$40.00price target onZYME(Zymeworks Inc.)
- Nov 4, 2025— Set$7.00price target onCRBU(Caribou Biosciences, Inc.)
- Oct 7, 2025— Set$39.00price target onRCUS(Arcus Biosciences, Inc.)
- Jul 15, 2025— Set$56.00price target onEXEL(Exelixis, Inc.)
- Oct 30, 2024— Set$38.00price target onEXEL(Exelixis, Inc.)
- Oct 14, 2024— Set$33.00price target onEXEL(Exelixis, Inc.)
- Aug 14, 2024— Set$83.00price target onGILD(Gilead Sciences, Inc.)
- Jun 24, 2024— Set$44.00price target onRCUS(Arcus Biosciences, Inc.)
- Aug 23, 2022— Set$3.00price target onCELU(Celularity Inc.)
Frequently Asked Questions
Who is Asthika Goonewardene?
Asthika Goonewardene is a stock analyst at Truist Financial covering 6 stocks primarily in Healthcare. They have issued 9 price targets since Aug 23, 2022.
What stocks does Asthika Goonewardene cover?
Asthika Goonewardene currently covers 6 stocks, including EXEL, RCUS, ZYME, CRBU, GILD.
What is Asthika Goonewardene's latest price target?
Asthika Goonewardene's most recent price target was $40.00 on ZYME (Zymeworks Inc.), set on Dec 17, 2025.
What is Asthika Goonewardene's highest price target?
Asthika Goonewardene's highest issued price target is $83.00 on GILD, set on Aug 14, 2024.
More Analysts at Truist Financial
Coverage based on publicly published price targets. Not investment advice.